XML 146 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]          
Pay vs Performance Disclosure, Table

Pay versus Performance

 

Pursuant to the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are required to provide the following information regarding the relationship between executive compensation paid to our named executive officers and Vericel’s financial performance for each of the last five completed calendar years. In determining the Compensation Actually Paid (or “CAP”) to our Principal Executive Officer, who is our CEO, and our other named executive officers, we are required to make various adjustments to the amounts that have been previously reported in the Summary Compensation Table, as summarized below. The CAP amounts reflected in the table below do not reflect the actual amount of compensation earned by or paid to our named executive officers during the applicable year. For information regarding decisions made by our Compensation Committee with respect to executive compensation, refer to the “Compensation Discussion and Analysis” section of this Proxy Statement.

   Summary
Compensation
Table Total
for CEO 		   Compensation
Actually
Paid to CEO(1)		   Average
Summary
Compensation
Table Total for
Other NEOs(2)		   Average
Compensation
Actually Paid
to Other
NEOs(1)(2)		   Value of Initial $100
Investment Based On:		         
Year                          Vericel
TSR(3)		      NASDAQ
Biotechnology
Index TSR(3)		      Net
Income
($M)(4)		      Total Net
Revenue
($M)(5)		 
2024   $10,237,525    $18,758,303     $2,703,655     $4,246,598        $316            $114      $10     $237 
2023  $7,056,422   $11,004,672   $1,918,083   $2,851,775   $205   $115   $-3   $198 
2022  $8,708,367   $905,166   $2,398,900   $467,192   $151   $111   $-17   $164 
2021  $13,183,295   $15,233,917   $3,459,670   $3,204,518   $226   $125   $-7   $156 
2020  $4,412,718   $10,300,425   $1,158,216   $1,740,344   $177   $126   $3   $124 
(1) To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation:

 

        CEO
        2020     2021     2022     2023     2024  
    Summary Compensation Table Total   $ 4,412,718     $ 13,183,295     $ 8,708,367     $ 7,056,422     $ 10,237,525  
Less:   Grant Date Fair Value of Stock and Option Awards in the Covered Year   -$ 3,218,783     -$ 11,819,409     -$ 7,288,603     -$ 5,513,083     -$ 8,680,435  
Plus:   Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year*   +$ 5,022,331     +$ 6,387,501     +$ 4,402,751     +$ 5,834,763     +$ 8,700,718  
Plus:   Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year*   +$ 522,347     +$ 1,618,248     +$ 724,137     +$ 711,181     +$ 1,038,836  
    Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years*   +$ 3,550,577     +$ 1,965,721     -$ 3,564,080     +$ 1,963,617     +$ 4,861,123  
    Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year*   +$ 11,235     +$ 3,898,560     -$ 2,077,406     +$ 951,771     +$ 2,600,537  
=   Compensation Actually Paid   $ 10,300,425     $ 15,233,917     $ 905,166     $ 11,004,672     $ 18,758,303  
                                             

        Average of Other NEOs
        2020     2021     2022     2023     2024  
    Summary Compensation Table Total   $ 1,158,216     $ 3,459,670     $ 2,398,900     $ 1,918,083     $ 2,703,655  
Less:   Grant Date Fair Value of Stock and Option Awards in the Covered Year   -$ 714,993     -$ 2,945,499     -$ 1,748,862     -$ 1,198,907     -$ 2,049,743  
Plus:   Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year*   +$ 756,348     +$ 1,626,544     +$ 1,056,425     +$ 1,275,999     +$ 2,095,233  
Plus:   Fair Value of Stock and Option Awards Granted  in the Covered Year that Vested in the Covered Year*   +$ 83,133     +$ 271,626     +$ 173,955     +$ 147,705     +$ 180,724  
    Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years*   +$ 636,734     +$ 299,760     -$ 902,246     +$ 445,775     +$ 832,854  
    Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year*   +$ 5,675     +$ 594,099     -$ 510,980     +$ 263,119     +$ 483,874  
Less:   Fair Value of Stock and Option Awards Forfeited During the Covered Year*   -$ 184,769     -$ 101,683     +$ 0     +$ 0     +$ 0  
=   Compensation Actually Paid   $ 1,740,344     $ 3,204,518     $ 467,192     $ 2,851,775     $ 4,246,598  

     
  * All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under ASC718 (refer to our Annual Report on Form 10-K for the year ending December 31, 2024 for additional detail).

(2) The other NEOs in each covered year were as follows:
  2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.

(3) TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.
(4) Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
(5) Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
        
Company Selected Measure Name Total Net Revenue        
Named Executive Officers, Footnote

(2) The other NEOs in each covered year were as follows:
  2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
        
Peer Group Issuers, Footnote TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.        
PEO Total Compensation Amount $ 10,237,525 $ 7,056,422 $ 8,708,367 $ 13,183,295 $ 4,412,718
PEO Actually Paid Compensation Amount [1] $ 18,758,303 11,004,672 905,166 15,233,917 10,300,425
Adjustment To PEO Compensation, Footnote [Text Block]

        CEO
        2020     2021     2022     2023     2024  
    Summary Compensation Table Total   $ 4,412,718     $ 13,183,295     $ 8,708,367     $ 7,056,422     $ 10,237,525  
Less:   Grant Date Fair Value of Stock and Option Awards in the Covered Year   -$ 3,218,783     -$ 11,819,409     -$ 7,288,603     -$ 5,513,083     -$ 8,680,435  
Plus:   Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year*   +$ 5,022,331     +$ 6,387,501     +$ 4,402,751     +$ 5,834,763     +$ 8,700,718  
Plus:   Fair Value of Stock and Option Awards Granted in the Covered Year that Vested in the Covered Year*   +$ 522,347     +$ 1,618,248     +$ 724,137     +$ 711,181     +$ 1,038,836  
    Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years*   +$ 3,550,577     +$ 1,965,721     -$ 3,564,080     +$ 1,963,617     +$ 4,861,123  
    Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year*   +$ 11,235     +$ 3,898,560     -$ 2,077,406     +$ 951,771     +$ 2,600,537  
=   Compensation Actually Paid   $ 10,300,425     $ 15,233,917     $ 905,166     $ 11,004,672     $ 18,758,303  
                                             
        
Non-PEO NEO Average Total Compensation Amount [2] $ 2,703,655 1,918,083 2,398,900 3,459,670 1,158,216
Non-PEO NEO Average Compensation Actually Paid Amount [1],[2] $ 4,246,598 2,851,775 467,192 3,204,518 1,740,344
Adjustment to Non-PEO NEO Compensation Footnote

        Average of Other NEOs
        2020     2021     2022     2023     2024  
    Summary Compensation Table Total   $ 1,158,216     $ 3,459,670     $ 2,398,900     $ 1,918,083     $ 2,703,655  
Less:   Grant Date Fair Value of Stock and Option Awards in the Covered Year   -$ 714,993     -$ 2,945,499     -$ 1,748,862     -$ 1,198,907     -$ 2,049,743  
Plus:   Fair Value at Year-End of Unvested Stock and Option Awards Granted in the Covered Year*   +$ 756,348     +$ 1,626,544     +$ 1,056,425     +$ 1,275,999     +$ 2,095,233  
Plus:   Fair Value of Stock and Option Awards Granted  in the Covered Year that Vested in the Covered Year*   +$ 83,133     +$ 271,626     +$ 173,955     +$ 147,705     +$ 180,724  
    Change in Fair Value of Unvested Stock and Option Awards Granted in Prior Years*   +$ 636,734     +$ 299,760     -$ 902,246     +$ 445,775     +$ 832,854  
    Change in Fair Value of Stock and Option Awards from Prior Years that Vested in the Covered Year*   +$ 5,675     +$ 594,099     -$ 510,980     +$ 263,119     +$ 483,874  
Less:   Fair Value of Stock and Option Awards Forfeited During the Covered Year*   -$ 184,769     -$ 101,683     +$ 0     +$ 0     +$ 0  
=   Compensation Actually Paid   $ 1,740,344     $ 3,204,518     $ 467,192     $ 2,851,775     $ 4,246,598  
        
Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid versus TSR 2020-2024

 

        
Compensation Actually Paid vs. Net Income

Compensation Actually Paid versus Net Income 2020-2024

 

        
Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid versus Revenue 2020-2024

 

        
Total Shareholder Return Vs Peer Group

 

        
Tabular List, Table

Tabular List of Financial Performance Measures

 

The following measures in our assessment represent the most important financial performance measures that link compensation actually paid to our named executive officers, for 2024, to Vericel’s performance:

 

1. Total Net Revenue
2. Stock Price
3. Budget expense (excluding depreciation, amortization and stock-based compensation, and unusual one-time expenses or changes in accounting methodology)
        
Total Shareholder Return Amount [3] $ 316 205 151 226 177
Peer Group Total Shareholder Return Amount [3] 114 115 111 125 126
Net Income (Loss) Attributable to Parent [4] $ 10,000,000 $ (3,000,000) $ (17,000,000) $ (7,000,000) $ 3,000,000
Company Selected Measure Amount [5] 237,000,000 198,000,000 164,000,000 156,000,000 124,000,000
Measure [Axis]: 1          
Pay vs Performance Disclosure [Table]          
Measure Name Total Net Revenue        
Measure [Axis]: 2          
Pay vs Performance Disclosure [Table]          
Measure Name Stock Price        
Measure [Axis]: 3          
Pay vs Performance Disclosure [Table]          
Measure Name Budget expense (excluding depreciation, amortization and stock-based compensation, and unusual one-time expenses or changes in accounting methodology)        
PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount $ (8,680,435) $ (5,513,083) $ (7,288,603) $ (11,819,409) $ (3,218,783)
PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 8,700,718 5,834,763 4,402,751 6,387,501 5,022,331
PEO [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 1,038,836 711,181 724,137 1,618,248 522,347
PEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 4,861,123 1,963,617 (3,564,080) 1,965,721 3,550,577
PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 2,600,537 951,771 (2,077,406) 3,898,560 11,235
Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount (2,049,743) (1,198,907) (1,748,862) (2,945,499) (714,993)
Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 2,095,233 1,275,999 1,056,425 1,626,544 756,348
Non-PEO NEO [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 180,724 147,705 173,955 271,626 83,133
Non-PEO NEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 832,854 445,775 (902,246) 299,760 636,734
Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] 483,874 263,119 (510,980) 594,099 5,675
Non-PEO NEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [6] $ 0 $ 0 $ 0 $ (101,683) $ (184,769)
[1] To calculate CAP, the following amounts were deducted from and added to the applicable Summary Compensation Table total compensation:
[2] The other NEOs in each covered year were as follows: 2024 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Karen Mahoney; 2023 – Joe Mara, Michael Halpin, Jonathan Hopper, Sean Flynn; 2022 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper; 2021 – Joe Mara, Michael Halpin, Sean Flynn, Jonathan Hopper, Sandra Pennell; 2020 – Michael Halpin, Sean Flynn, Jonathan Hopper, Gerard Michel, Sandra Pennell.
[3] TSR is cumulative for the measurement period, calculated in accordance with Item 201(e) of Regulation S-K. Our TSR Peer Group are members of the NASDAQ Biotechnology Index.
[4] Reflects net Income as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
[5] Reflects total net revenue, the “company-selected measure” as shown in the Company’s Annual Report on Form 10-K for the years ending on December 31, 2024, 2023, 2022, 2021 and 2020.
[6] All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under ASC718 (refer to our Annual Report on Form 10-K for the year ending December 31, 2024 for additional detail).